Ticker Details
Theravance Biopharma, Inc. Theravance Biopharma Inc is a diversified biopharmaceutical company. It is engaged in discovery, research, development and commercialization of human therapeutics.
IPO Date:	May 16, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$880.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.42 | 2.28%
Avg Daily Range (30 D):	$0.24 | 1.41%
Avg Daily Range (90 D):	$0.26 | 1.63%

Institutional Daily Volume
Avg Daily Volume:	.34M
Avg Daily Volume (30 D):	.52M
Avg Daily Volume (90 D):	.48M

Trade Size
Avg Trade Size (Sh.):	88
Avg Trade Size (Sh.) (30 D):	67
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	2,306
Avg Institutional Trade:	$1.41M
Avg Institutional Trade (30 D):	$2.03M
Avg Institutional Trade (90 D):	$1.73M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.23M
Avg Closing Trade (30 D):	$2.61M
Avg Closing Trade (90 D):	$1.97M
Avg Closing Volume:	77.35K

News

Jun 29, 2026 @ 10:00 AM Zymeworks to Acquire Theravance Biopharma, Inc. Source: Na

Apr 3, 2026 @ 12:48 AM TBPH Investors Have Opportunity to Join Theravance... Source: Schall Law Firm

Mar 3, 2026 @ 6:19 PM Theravance Biopharma Plummets As Phase 3 Study Fal... Source: Vandana Singh

Feb 22, 2026 @ 3:08 PM Irenic Dumps Most Papa John's Shares Source: Lawrence Rothman, Cfa

Jan 19, 2026 @ 12:37 PM Neurogenic Orthostatic Hypotension (nOH) Global Cl... Source: Researchandmarkets.Com

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.26	$-.1	$1.2
Diluted EPS	$2.2	$-.1	$1.15
Revenue	$109.78M	$17.7M	$45.89M
Gross Profit
Net Income / Loss	$114.54M	$-4.93M	$61.02M
Operating Income / Loss	$1.35M	$-9.48M	$20.01M
Cost of Revenue
Net Cash Flow	$177.49M	$120.3M	$-6.97M
PE Ratio